Navigation Links
University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
Date:8/15/2012

MIAMI, Aug. 15, 2012 /PRNewswire/ -- A published University of Miami study using Rice Bran Arabinoxylan Compound (RBAC) has showed  RBAC demonstrated significant immunomodulary activity based upon the observed changes in natural killer cell cytotoxicity (NKCC) and the cytokines and growth factors. Specifically, the study showed that the short term rise in NKCC and in 9 of 12 cytokines and growth factors are evident that RBAC is a potent immunomodulator. The study was published July 28, 2012 in Functional Foods in Health and Disease (Volume 2, Issue 7), http://functionalfoodscenter.net/The_Journal_of_FFHD__Page_3.html.

RBAC may help to destroy tumor cells and viruses directly, and increase the activity of immune cells, thereby optimizing the immune system, especially NKCC, which can increase the chance and speed of host recovery. Researchers note that the immunomodulatory activity merits further study in conditions where the immune system is functionally compromised, such as otherwise healthy smokers and HIV/AIDS or cancer patients.

RBAC is a nutritional supplement produced by enzymatic hydrolysis of hemicellulose B derived from rice bran. Several in vitro studies and clinical reports have shown RBAC to possess promising immunomodulating effects, specifically with respect to natural killer cell and cytokine activity.

The concept of a true immunomodulator is an agent possessing a broad range of activity dependent upon the existing state of health and immunity in the individual host. The Miami University study investigated the immunomodulatory effect of RBAC in a healthy adult human population over 60 days by assessing changes in NKCC and cytokines and growth factors.

According to Dr. John Lewis, Ph.D. associate professor, department of psychiatry and behavioral sciences at the University of Miami, Miller School of Medicine, and corres
'/>"/>

SOURCE Daiwa Health Development
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
2. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
3. Worlds smallest semiconductor laser created by University of Texas scientists
4. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
5. University of Utah physicists invent spintronic LED
6. University of Nottingham to play key role in European solar energy technology project
7. Western Carolina University, College of Business Appoints New Director of Entrepreneurship and Innovation
8. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
9. University of Utah chemists use nanopores to detect DNA damage
10. Stevenage Bioscience Catalyst to Welcome Cambridge University Researchers
11. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor ... 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Rapid Production, Increased Bioavailability, MOUNTAIN VIEW, Calif., ... are either incurable or difficult to treat allures ... prized, due to their,therapeutic potential, stem cell therapies ... Stem cell research progresses at a fast pace; ...
... Inc. (Nasdaq: CEPH ) and Eurand NV ... Paragraph IV Certification Notice Letter on October 20, ... to the U.S.,Food and Drug Administration (FDA) by ... a generic version of the 15 mg and,30 ...
... 71% of Evaluable Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... Second Stage-, TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... cancer and serious viral,infections, today announced that updated preliminary data from ...
Cached Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... 2005 discovery of an enzyme that is a natural ... Diego (UCSD) School of Medicine have now identified two ... for therapies to treat diabetes, heart and neurological disease. ... professor of pharmacology, and colleagues are published in the ...
... years, orthopedic surgeon Dennis Crawford, M.D., Ph.D., of Oregon ... tissue for transplant to treat some of his patients ... this unfortunate and ironic," explained Crawford, assistant professor of ... and a specialist in sports medicine. "Oregonians, it turns ...
... cancer care was $2.3 billion in the first year after diagnosis, ... the Journal of the National Cancer Institute . The time ... cancer care varied widely, they write. , Several studies have ... attempted to include a patient's time associated with cancer care, such ...
Cached Biology News:UCSD researchers discover variants of natural tumor suppressor 2OHSU surgeon implants donated tissue allografts 2Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3
... Mouse monoclonal [PRMT5-21] to PRMT5 Arginine ... which has only recently been linked to ... PRMT enzymes have been identified in mammalian ... have essential regulatory functions by methylation of ...
... complete kit contains enough separation ... a total of 5 x ... includes the StemSep red magnet ... and buffers for the specific ...
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
... dehydrogenase catalyzes a reversible reaction between ... with NAD as a coenzyme. GPDH ... progenitor cells into adipocytes and, thus, ... been used as an index for ...
Biology Products: